Early research shows that the drug Remdesivir might be a potential Cornavirus treament. Remdesivir may help very sick patients improve their breathing, though experts caution that more studies are needed before the drug, remdesivir, can be recommended. Remdesivir was used for the first person diagnosed with Coronavirus in the U.S. and it showed to have helped that patient.
Remdesivir is an antiviral therapy is thought to work by blocking the virus from replicating itself. The study however, did not provide any information on whether the drug actually worked by reducing levels of the virus in patients’ bodies. Gilead, which was involved in the previously research, has begun enrolling up to a thousand patients for clinical trials on remdesivir. The largest dataset available on remdesivir, 53 patients so far is still limited, and experts cautioned against drawing conclusions that the drug works. Researchers published the data in The New England Journal of Medicine, a top medical journal.
“Currently there is no proven treatment for COVID-19. We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful,” Dr. Jonathan Grein, director of hospital epidemiology at Cedars-Sinai Medical Center, said in an April 10 statement. Clinical trials are underway for remdesivir that will provide a better understanding.
Two studies are being done in China, are going to give results in mid-April. Gilead Chief Medical Officer Merdad Parsey called the data “encouraging” but “limited.”The report still brings some hope, given that some patients have seen some level of clinical improvement since taking remdesivir.
COVID-19 has now infected nearly 2 million people with 108,000 deaths worldwide. Currently the U.S. is in their peak days.week with New York City for the third day alone having a death toll of 700+. At this moment whole world is rapidly looking for a cure for COVID-19, with everyone working together, the cure could be right around the corner.
For more news on COVID-19 please subscribe to our site.